Clinical trial
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe…
NCT00073047 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00073047 |
|---|---|
| Title | Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis |
| Official title | A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 150 |
| Start date | Apr 1, 2003 |
| Completion | Jul 1, 2006 |
| First posted | Nov 18, 2003 |
| Last update posted | Jul 20, 2009 |
| Countries | Belgium, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: